[1] Hegi ME, Stupp R. Neuro-oncology: in search of molecular markers of glioma in elderly patients[J].Nat Rev Neurol,2013, 9(8):424-425.
[2] 汪丹,陈小来.不同级别颅脑胶质瘤患者外科治疗后的细胞免疫状况研究[J].医学临床研究,2016, 33(8):1489-1491.
[3] Gonzalez-Quarante LH.Angiocentric glioma in an elderly patient: case report and review of the literature[J].World Neurosurg,2017, 97:755.
[4] Saito T, Sugiyama K, Takeshima Y, et al. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide[J].J Neurosurg,2018,128(3):679-684.
[5] Quick-Weller J. "Two is not enough" -Impact of thenumber of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma[J].J Clin Neuroscim,2018,47:311.
[6] Kellermann SG, Hamisch CA, Rue D, et al. Stereotactic biopsy in elderly patients: risk assessment and impact on treatment decision[J].J Neurooncol,2017,134(2):303-307.
[7] 何洁,万经海,李学记, 等.老年胶质瘤临床分析[J].中国微侵袭神经外科杂志,2015,20(4):148-149.
[8] Donato V, Monaco A, Rollo A, et al. Elderly and poor prognosis patients with high grade glioma: hypofractionated radiotherapy[J].Clin Ther,2007,158(3):227-230.
[9] Perry JR, Laperriere N, O'Callaghan CJ, et al.; Trial investigators. short-course radiation plus temozolomide in elderly patients with glioblastoma[J].N Engl J Med,2017,376(11):1027-1037.
[10] Kellermann SG, Hamisch CA, Rue D, et al. Stereotactic biopsy in elderly patients: risk assessment and impact on treatment decision[J].J Neurooncol,2017,134(2):303-307. |
2018, Vol. 35 
